Kymera Investor Presentation Deck

● ● Part C Summary KT-474 administered to HS and AD patients at 75 mg QD for 28 days shown to have safety, PK and PD comparable to healthy volunteers Modest, non-adverse QTcF prolongation observed to spontaneously resolve back to baseline during final 2 weeks of dosing in HS and AD patients Robust degradation of IRAK4 in blood and skin was associated with systemic anti- inflammatory effect in HS and AD patients Promising clinical activity observed in HS and AD exceeding benchmark placebo rates and comparing favorably to SOC biologics Data presented here validate IRAK4 degradation as a potential best in class mechanism in inflammatory diseases and its superior clinical potential over SMI Results support advancing KT-474 into Phase 2 placebo-controlled trials, Sanofi has committed to start Ph2 clinical trials initially in HS and AD KYMERA ©2023 KYMERA THERAPEUTICS, INC. PAGE 33

View entire presentation